1. Home
  2. IPHA vs GPMT Comparison

IPHA vs GPMT Comparison

Compare IPHA & GPMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • GPMT
  • Stock Information
  • Founded
  • IPHA 1999
  • GPMT 2015
  • Country
  • IPHA France
  • GPMT United States
  • Employees
  • IPHA N/A
  • GPMT N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • GPMT Real Estate Investment Trusts
  • Sector
  • IPHA Health Care
  • GPMT Real Estate
  • Exchange
  • IPHA Nasdaq
  • GPMT Nasdaq
  • Market Cap
  • IPHA 160.1M
  • GPMT 148.4M
  • IPO Year
  • IPHA 2019
  • GPMT 2017
  • Fundamental
  • Price
  • IPHA $2.24
  • GPMT $2.87
  • Analyst Decision
  • IPHA Strong Buy
  • GPMT Buy
  • Analyst Count
  • IPHA 1
  • GPMT 4
  • Target Price
  • IPHA $11.50
  • GPMT $3.63
  • AVG Volume (30 Days)
  • IPHA 650.0K
  • GPMT 372.0K
  • Earning Date
  • IPHA 03-20-2025
  • GPMT 02-13-2025
  • Dividend Yield
  • IPHA N/A
  • GPMT 6.97%
  • EPS Growth
  • IPHA N/A
  • GPMT N/A
  • EPS
  • IPHA N/A
  • GPMT N/A
  • Revenue
  • IPHA $36,202,722.00
  • GPMT N/A
  • Revenue This Year
  • IPHA N/A
  • GPMT N/A
  • Revenue Next Year
  • IPHA $93.37
  • GPMT $29.28
  • P/E Ratio
  • IPHA N/A
  • GPMT N/A
  • Revenue Growth
  • IPHA N/A
  • GPMT N/A
  • 52 Week Low
  • IPHA $1.29
  • GPMT $2.46
  • 52 Week High
  • IPHA $3.51
  • GPMT $5.02
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 63.01
  • GPMT 46.42
  • Support Level
  • IPHA $2.07
  • GPMT $2.66
  • Resistance Level
  • IPHA $2.38
  • GPMT $3.19
  • Average True Range (ATR)
  • IPHA 0.13
  • GPMT 0.15
  • MACD
  • IPHA 0.04
  • GPMT -0.01
  • Stochastic Oscillator
  • IPHA 78.79
  • GPMT 40.19

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About GPMT Granite Point Mortgage Trust Inc.

Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning, and repurposing of the property.

Share on Social Networks: